7 results about "Interferon beta" patented technology

The present invention relates to a dry powder formulation of interferon beta and a method for preparing the same, and more particularly, to a dry powder formulation of interferon beta in the form of spherical particles having high morphological integrity prepared by spray drying a liquid composition containing interferon beta, and a method for preparing the dry powder formulation of interferon beta.

Provided herein are methods for treating a brachyury-associated cancer or neoplasm, e.g., chordoma, with a type I interferon in a subject in need thereof. The methods further include treating the brachyury-associated cancer or neoplasm with interferon alpha or interferon beta by injection of interferon protein into a subject in need thereof, wherein the interferon can be an interferon polypeptide or an interferon nucleic acid formulated for expression.

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFNβ). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.

Disclosed herein are engineered, non-naturally occurring protein variants with de novo glycosylation sites having wildtype-like biological activity of wildtype interferon beta. Also disclosed herein are vectors encoding the non-naturally occurring protein variants described herein. Also disclosed herein are pharmaceutical compositions comprising the non-naturally occurring protein variants described herein or a vector encoding the non-naturally occurring protein variants described herein. Also disclosed herein are methods of treating a disease by administering to a subject the non-naturally occurring protein variants described herein, a vector encoding the non-naturally occurring protein variants described herein, or a pharmaceutical composition comprising the non-naturally occurring protein variants described herein or a vector described herein.

Disclosed herein are engineered, non-naturally occurring protein variants with de novo glycosylation sites having wildtype-like biological activity of wildtype interferon beta. Also disclosed herein are vectors encoding the non-naturally occurring protein variants described herein. Also disclosed herein are pharmaceutical compositions comprising the non-naturally occurring protein variants described herein or a vector encoding the non-naturally occurring protein variants described herein. Also disclosed herein are methods of treating a disease by administering to a subject the non-naturally occurring protein variants described herein, a vector encoding the non-naturally occurring protein variants described herein, or a pharmaceutical composition comprising the non-naturally occurring protein variants described herein or a vector described herein.

To provide a pharmaceutical composition for restraining self-replication infection of respiratory viruses in a subject exposed to potential respiratory virus infection, the composition comprising interferon-beta as an active ingredient.SOLUTION: Provided is a pharmaceutical composition for pre-exposure prophylaxis or post-exposure prophylaxis of infection by a coronavirus, an influenza virus, or an RS virus in a subject, the composition comprising mutant interferon-beta as an active ingredient, the mutant interferon-beta being administered by inhalation and the mutant interferon-beta comprising a substitution of threonine at arginine 27 of wild-type interferon-beta.SELECTED DRAWING: None

This invention provides methods for treating acute respiratory distress syndrome (ARDS), including ARDS associated with respiratory viral infections. [Solution] Administer plasma kallikrein (pKal) inhibitors such as anti-pKal antibodies as inhibitors of the contact activation pathway. Immunomodulators such as IL-6R inhibitors, antiviral agents such as lopinavir, ritonavir, interferon beta, umfenovir, and remdesivir, antimalarial agents such as chloroquine, and / or inhibitors of the contact activation pathway such as C1 inhibitors, pKal inhibitors, and bradykinin receptor antagonists may be administered to the patient as additional therapeutic agents.